Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02147639|
Recruitment Status : Unknown
Verified May 2014 by Ron Victor, Cedars-Sinai Medical Center.
Recruitment status was: Recruiting
First Posted : May 28, 2014
Last Update Posted : May 28, 2014
|Condition or disease||Intervention/treatment||Phase|
|Becker Muscular Dystrophy||Dietary Supplement: Sodium Nitrate Dietary Supplement: Sodium Nitrate - double dose Dietary Supplement: Placebo Procedure: Increased exercise intensity||Phase 2 Phase 3|
There are 2 phases to this research project: (1) an initial baseline study to confirm the blood flow abnormality in Becker muscular dystrophy, and (2) a subsequent brief treatment trial. There are also 3 optional study protocols: (A) dose-escalation trial, (B) placebo trial, and (C) increased exercise intensity trial.
The baseline study involves an intake history, physical examination, and phlebotomy for blood chemistries and DNA followed by non-invasive forearm blood flow studies (Near Infrared Spectroscopy, Doppler Ultrasound) before and after a brief bout of handgrip exercise (approximately 3-5 hours to complete). Blood flow studies will be performed with the subject's lower body enclosed in an airtight chamber. Blood flow and oxygen delivery to the forearm muscles will be measured before and during application of lower body negative pressure at rest and during handgrip exercise. Lower body negative pressure simulates the blood flow changes that normally occur when a person sits up after lying down.
The results of the baseline study will determine which patients meet preset eligibility criteria to participate in the medication phase of the study. These criteria include (1) normal kidney and liver function tests and normal BNP levels (the latter to exclude heart failure), and (2) abnormal blood flow responses to handgrip exercise.
Eligible patients will be asked to repeat the above laboratory procedures on a subsequent study day after receiving a single dose of sodium nitrate. Eligible patients will also be offered the option to repeat the above laboratory procedures on three subsequent study visits, where upon: (A) the dose of sodium nitrate is increased, (B) a placebo is ingested, and/or (C) the level of exercise in increased.
The investigators plan to enroll 20 adult men with Becker muscular dystrophy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||May 2014|
|Estimated Study Completion Date :||May 2014|
Experimental: Sodium Nitrate
Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
Dietary Supplement: Sodium Nitrate
No Intervention: Baseline
This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
Experimental: Dose-escalation trial
This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
Dietary Supplement: Sodium Nitrate - double dose
Placebo Comparator: Placebo-control trial
This is an optional study visit, where patients will ingest a placebo.
Dietary Supplement: Placebo
Experimental: Increased exercise intensity
This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
Procedure: Increased exercise intensity
- Skeletal muscle blood flow [ Time Frame: 24 hours after initial visit ]Skeletal muscle blood flow regulation will be assessed at each visit by near infrared spectroscopy and Doppler ultrasound.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02147639
|Contact: Michael D Nelson, PhDfirstname.lastname@example.org|
|United States, California|
|Cedars-Sinai Heart Institute||Recruiting|
|Los Angeles, California, United States, 90048|
|Contact: Michael D Nelson, PhD 310-967-3844 email@example.com|
|Principal Investigator:||Ronald G Victor, MD||Cedars-Sinai Medical Center|